SecBot SecBot
SECBOTREPLAY Home › Report › OCGN

OCGN · Ocugen reported Q4 and full-year 2025 financial results showing…

Ocugen · PRESS-RELEASE filed Mar 4, 2026 at 08:15 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 4, 2026 at 08:15 ET

Ocugen reported Q4 and full-year 2025 financial results showing increased R&D spending and a wider net loss, while highlighting clinical progress across its gene therapy pipeline, including completed Phase 3 enrollment for OCU400 and positive preliminary Phase 2 data for OCU410 in geographic atrophy. The company extended its cash runway into Q4 2026 via a $22.5M financing, with potential extension to Q2 2027 if warrants are exercised.

  • Completed enrollment in OCU400 Phase 3 trial for retinitis pigmentosa; topline data expected Q1 2027.
  • Positive preliminary Phase 2 data for OCU410 in geographic atrophy: 46% lesion growth reduction (p=0.015), 50% responder rate with >50% reduction.
  • OCU410ST Phase 2/3 trial for Stargardt disease nearing enrollment completion; interim data expected Q3 2026.
  • Secured $22.5M in gross proceeds in January 2026; cash runway extended to Q4 2026, potentially Q2 2027 with full warrant exercise.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access